Full Press Release Details
Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, July 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) investors of a class action representing investors that bought securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"). Iovance investors have until July 14, 2025 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
According to the lawsuit, during the Class Period, Defendants made false or misleading statements and/or failed to disclose that: (1) newly authorized treatment centers (“ATCs”) faced delays in initiating patient treatments with Amtagvi; (2) Iovance’s sales team and ATCs struggled with effective patient identification and selection, resulting in higher patient drop-off rates; (3) these issues led to increased costs and reduced revenue, as ATCs could not match the pace of product manufacturing; and (4) consequently, Defendants’ positive statements regarding Iovance’s business, operations, and outlook were materially misleading or lacked a reasonable basis. The lawsuit alleges that investors suffered losses when the truth was revealed to the market.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising